290 related articles for article (PubMed ID: 38223409)
1. Strategies to overcome low MHC-I expression in paediatric and adult tumours.
Guillaume J; Perzolli A; Boes M
Immunother Adv; 2024; 4(1):ltad028. PubMed ID: 38223409
[TBL] [Abstract][Full Text] [Related]
2. MHC-II neoantigens shape tumour immunity and response to immunotherapy.
Alspach E; Lussier DM; Miceli AP; Kizhvatov I; DuPage M; Luoma AM; Meng W; Lichti CF; Esaulova E; Vomund AN; Runci D; Ward JP; Gubin MM; Medrano RFV; Arthur CD; White JM; Sheehan KCF; Chen A; Wucherpfennig KW; Jacks T; Unanue ER; Artyomov MN; Schreiber RD
Nature; 2019 Oct; 574(7780):696-701. PubMed ID: 31645760
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
4. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
Quinn LL; Williams LR; White C; Forrest C; Zuo J; Rowe M
J Virol; 2016 Jan; 90(1):356-67. PubMed ID: 26468525
[TBL] [Abstract][Full Text] [Related]
5. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
6. Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F; Aptsiauri N
Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
[TBL] [Abstract][Full Text] [Related]
7. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy.
Cornel AM; Mimpen IL; Nierkens S
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630675
[TBL] [Abstract][Full Text] [Related]
8. Immune contexture of paediatric cancers.
Thakur MD; Franz CJ; Brennan L; Brouwer-Visser J; Tam R; Korski K; Koeppen H; Ziai J; Babitzki G; Ranchere-Vince D; Vasiljevic A; Dijoud F; Marec-Bérard P; Rochet I; Cannarile MA; Marabelle A
Eur J Cancer; 2022 Jul; 170():179-193. PubMed ID: 35660252
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.
Símová J; Polláková V; Indrová M; Mikyšková R; Bieblová J; Stěpánek I; Bubeník J; Reiniš M
Br J Cancer; 2011 Nov; 105(10):1533-41. PubMed ID: 22015556
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response.
Taylor BC; Balko JM
Front Immunol; 2022; 13():844866. PubMed ID: 35296095
[TBL] [Abstract][Full Text] [Related]
11. Tumour MHC class I downregulation and immunotherapy (Review).
Bubeník J
Oncol Rep; 2003; 10(6):2005-8. PubMed ID: 14534734
[TBL] [Abstract][Full Text] [Related]
12. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
[TBL] [Abstract][Full Text] [Related]
13. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
14. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
[TBL] [Abstract][Full Text] [Related]
15. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer.
Simpson JA; Al-Attar A; Watson NF; Scholefield JH; Ilyas M; Durrant LG
Gut; 2010 Jul; 59(7):926-33. PubMed ID: 20581241
[TBL] [Abstract][Full Text] [Related]
17. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours.
Seo H; Jeon I; Kim BS; Park M; Bae EA; Song B; Koh CH; Shin KS; Kim IK; Choi K; Oh T; Min J; Min BS; Han YD; Kang SJ; Shin SJ; Chung Y; Kang CY
Nat Commun; 2017 Jun; 8():15776. PubMed ID: 28585539
[TBL] [Abstract][Full Text] [Related]
18. Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours.
Reinis M; Símová J; Indrová M; Bieblová J; Pribylová H; Moravcová S; Jandlová T; Bubeník J
Int J Oncol; 2007 Apr; 30(4):1011-7. PubMed ID: 17332942
[TBL] [Abstract][Full Text] [Related]
19. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
20. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
